3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Obesity
9
Endometrial Neoplasms
5
Prostatic Neoplasms
2
Overweight
2
Diabetes Mellitus
2
Breast Neoplasms
2
Weight Loss
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Opioid-Related Disorders
1
Metabolic Syndrome
1
Lymphoma, Follicular
1
Insulin Resistance
1
Inflammation
1
Hyperplasia
1
Endometrial Hyperplasia
1
Dyslipidemias
1
Colorectal Neoplasms
1
Interventions
Cyclophosphamide
176
Rituximab
164
fludarabine phosphate
97
Peripheral Blood Stem Cell Transplantation
95
Filgrastim
73
Etoposide
67
Radiotherapy
63
Mycophenolic Acid
62
Whole-Body Irradiation
58
Tacrolimus
49
Melphalan
49
Cyclosporine
49
Busulfan
47
Lenalidomide
45
Antilymphocyte Serum
39
Vincristine
37
Prednisone
37
Cytarabine
37
fludarabine
35
Methotrexate
33
Carmustine
32
obinutuzumab
31
Doxorubicin
30
Bendamustine Hydrochloride
30
Methylprednisolone
27
ibritumomab tiuxetan
25
Cord Blood Stem Cell Transplantation
25
sargramostim
24
Bortezomib
24
Granulocyte Colony-Stimulating Factor
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, Follicular
×
Tirzepatide
×
Clear all
NCT06651177
2026-05-22
TAB
University of Cincinnati
Phase 2
Recruiting
310 enrolled